References
- Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23. https://doi.org/10.1016/0002-9343(94)90131-7
- Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998;27:465-83. https://doi.org/10.1016/S0889-8529(05)70017-7
- Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-9. https://doi.org/10.1002/art.11283
- Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004;15:323-8. https://doi.org/10.1007/s00198-003-1548-3
- Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006;39:253-9. https://doi.org/10.1016/j.bone.2006.02.005
- Feldstein AC, Elmer PJ, Nichols GA, et al. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005;16:2168-74. https://doi.org/10.1007/s00198-005-2016-z
- Salerno A, Hermann R. Efficacy and safety of steroid use for postoperative pain relief. Update and review of the medical literature. J Bone Joint Surg Am 2006;88:1361-72. https://doi.org/10.2106/00004623-200606000-00029
- Fardet L, Petersen I, Nazareth I. Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study. Medicine (Baltimore) 2015;94:e647. https://doi.org/10.1097/MD.0000000000000647
- Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000;93:105-11. https://doi.org/10.1093/qjmed/93.2.105
- Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87. https://doi.org/10.1007/s001980200108
- LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990;8:39-51. https://doi.org/10.1016/0169-6009(91)90139-Q
- Kim D, Cho SK, Park B, et al. Glucocorticoids are associated with an increased risk for vertebral fracture in patients with rheumatoid arthritis. J Rheumatol 2018;45:612-20. https://doi.org/10.3899/jrheum.170054
- Weinstein RS. True strength. J Bone Miner Res 2000;15:621-5.
- Leslie WD. The importance of spectrum bias on bone density monitoring in clinical practice. Bone 2006;39:361-8. https://doi.org/10.1016/j.bone.2006.02.002
- Seeman E, Delmas PD. Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354:2250-61. https://doi.org/10.1056/NEJMra053077
- Buckley L, Guyatt G, Fink HA, et al. 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2017;69:1095-110. https://doi.org/10.1002/acr.23279
- Van Staa TP, Geusens P, Pols HA, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005;98:191-8. https://doi.org/10.1093/qjmed/hci029
- Hall GM, Spector TD, Griffin AJ, et al. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 1993;36:1510-6. https://doi.org/10.1002/art.1780361105
- Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993;119:963-8. https://doi.org/10.7326/0003-4819-119-10-199311150-00001
- Kim SY, Jee SM, Lee SJ, et al. Guidance for development of clinical practice guidelines. ver 1.0. Seoul: National Evidence-based Healthcare Collaborating Agency; 2011.
- Grossman JM, Gordon R, Ranganath VK, et al. American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515-26. https://doi.org/10.1002/acr.20295
- Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012; 23:2257-76. https://doi.org/10.1007/s00198-012-1958-1
- Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-73. https://doi.org/10.1503/cmaj.100771
- Briot K, Cortet B, Roux C, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine 2014;81:493-501. https://doi.org/10.1016/j.jbspin.2014.10.001
- Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 2012;52:580-93. https://doi.org/10.1590/S0482-50042012000400009
- Suzuki Y, Nawata H, Soen S, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 2014;32:337-50. https://doi.org/10.1007/s00774-014-0586-6
- Rossini M, Adami S, Bertoldo F, et al. Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 2016;68:1-39. https://doi.org/10.4081/reumatismo.2016.870
- Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol 2010;63:1308-11. https://doi.org/10.1016/j.jclinepi.2010.07.001
- Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017;12:43. https://doi.org/10.1007/s11657-017-0324-5
- Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011;22:809-16. https://doi.org/10.1007/s00198-010-1524-7
- Kaji H, Yamauchi M, Chihara K, et al. Glucocorticoid excess affects cortical bone geometry in premenopausal, but not postmenopausal, women. Calcif Tissue Int 2008;82:182-90. https://doi.org/10.1007/s00223-008-9106-9
- Fassio A, Idolazzi L, Jaber MA, et al. The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis. Reumatismo 2016;68:65-71. https://doi.org/10.4081/reumatismo.2016.878
- Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28. https://doi.org/10.1007/s00198-007-0394-0
- Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52. https://doi.org/10.1056/NEJM199306173282404
- Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001;16:104-12. https://doi.org/10.1359/jbmr.2001.16.1.104
- Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 1996;23:995-1000.
- Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-8. https://doi.org/10.7326/0003-4819-125-12-199612150-00004
- Braun JJ, Birkenhager-Frenkel DH, Rietveld AH, et al. Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study. Clin Endocrinol (Oxf) 1983;19:265-73. https://doi.org/10.1111/j.1365-2265.1983.tb02989.x
- Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999;9:75-81. https://doi.org/10.1007/s001980050118
- Okada Y, Nawata M, Nakayamada S, et al. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 2008;35:2249-54. https://doi.org/10.3899/jrheum.080168
- Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9. https://doi.org/10.1056/NEJM199807303390502
- Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11. https://doi.org/10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W
- Lems WF, Lodder MC, Lips P, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2006; 17:716-23. https://doi.org/10.1007/s00198-005-0037-2
- Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 2009;36:1705-14. https://doi.org/10.3899/jrheum.081207
- Tee SI, Yosipovitch G, Chan YC, et al. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. Arch Dermatol 2012;148:307-14. https://doi.org/10.1001/archdermatol.2011.354
- Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67: 277-85. https://doi.org/10.1007/s002230001146
- Yamada S, Takagi H, Tsuchiya H, et al. Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients. Yakugaku Zasshi 2007;127:1491-6. https://doi.org/10.1248/yakushi.127.1491
- Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18. https://doi.org/10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K
- Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009;373:1253-63. https://doi.org/10.1016/S0140-6736(09)60250-6
- Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009;20:2095-104. https://doi.org/10.1007/s00198-009-0917-y
- Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 2018;6:445-54. https://doi.org/10.1016/S2213-8587(18)30075-5
- Candelas G, Martinez-Lopez JA, Rosario MP, et al. Calcium supplementation and kidney stone risk in osteoporosis: a systematic literature review. Clin Exp Rheumatol 2012;30: 954-61.
- Lewis JR, Radavelli-Bagatini S, Rejnmark L, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res 2015;30:165-75. https://doi.org/10.1002/jbmr.2311
- de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675-84. https://doi.org/10.1056/NEJMoa053569
- Yilmaz L, Ozoran K, Gunduz OH, et al. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 2001;20:65-9. https://doi.org/10.1007/s002960000080
- Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000;11:331-7. https://doi.org/10.1007/s001980070122
- Reid DM, Adami S, Devogelaer JP, et al. Risedronate increases bone density and reduces vertebral fracture risk with in one year in men on corticosteroid therapy. Calcif Tissue Int 2001;69:242-7. https://doi.org/10.1007/s00223-001-1060-8
- Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000;15:1006-13. https://doi.org/10.1359/jbmr.2000.15.6.1006
- Hakala M, Kroger H, Valleala H, et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol 2012;41:260-6. https://doi.org/10.3109/03009742.2012.664647
- Sambrook PN, Roux C, Devogelaer JP, et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 2012;50:289-95. https://doi.org/10.1016/j.bone.2011.10.024
- Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102. https://doi.org/10.1056/NEJM200507073530120
- Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009;67:850-5. https://doi.org/10.1016/j.joms.2008.11.015
- Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. https://doi.org/10.7326/0003-4819-144-10-200605160-00009
- Giusti A, Hamdy NA, Dekkers OM, et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011;48:966-71. https://doi.org/10.1016/j.bone.2010.12.033
- Edwards MH, McCrae FC, Young-Min SA. Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int 2010;21:701-3. https://doi.org/10.1007/s00198-009-0986-y
- Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89:349-53.
- Ing-Lorenzini K, Desmeules J, Plachta O, et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009;32:775-85. https://doi.org/10.2165/00002018-200932090-00002
- Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224-31. https://doi.org/10.1016/j.injury.2007.08.036
- Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29:1-23. https://doi.org/10.1002/jbmr.1998
- Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-33. https://doi.org/10.1172/JCI3914
- Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60:3346-55. https://doi.org/10.1002/art.24879
- Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39. https://doi.org/10.1056/NEJMoa071408
- Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010;69:872-5. https://doi.org/10.1136/ard.2009.112920
- Mok CC, Ying KY, To CH, et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 2011;70:778-84. https://doi.org/10.1136/ard.2010.143453
- Patlas N, Golomb G, Yaffe P, et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999;60:68-73. https://doi.org/10.1002/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H
- Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009; 44:428-30. https://doi.org/10.1016/j.bone.2008.11.001
- Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 2006;22:578-9. https://doi.org/10.1016/j.reprotox.2006.05.009
- Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016. Endocr Pract 2016;22:1-42.
Cited by
- Treatment of Glucocorticoid-Induced Osteoporosis with Bisphosphonates Alone, Vitamin D Alone or a Combination Treatment in Eastern Asians: A Meta-Analysis vol.25, pp.14, 2018, https://doi.org/10.2174/1381612825666190619125426
- Evaluation of the effect of CaD on the bone structure and bone metabolic changes in senile osteoporosis rats based on MLP-ANN methods vol.10, pp.12, 2018, https://doi.org/10.1039/c9fo01322a
- 간이식 후 골다공증 관리 vol.30, pp.1, 2018, https://doi.org/10.24304/kjcp.2020.30.1.51
- Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment vol.16, pp.8, 2018, https://doi.org/10.1038/s41574-020-0341-0
- Physicians’ Attitudes on Management of Osteopenia in South Korea vol.27, pp.3, 2018, https://doi.org/10.11005/jbm.2020.27.3.201
- Effect of glucocorticoids on bone metabolism in replacement therapy of adrenal insufficiency. Literature review vol.17, pp.4, 2018, https://doi.org/10.14341/omet12700
- Fracture Risk and Its Prevention Patterns in Korean Patients with Polymyalgia Rheumatica: a Retrospective Cohort Study vol.36, pp.42, 2018, https://doi.org/10.3346/jkms.2021.36.e263
- Therapies for Preventing Bone Loss with Glucocorticoid Treatment vol.19, pp.1, 2018, https://doi.org/10.1007/s11914-020-00653-9
- Update on Glucocorticoid Induced Osteoporosis vol.36, pp.3, 2018, https://doi.org/10.3803/enm.2021.1021
- Discriminative ability of trabecular bone score over bone mineral density for vertebral and fragility fracture in patients treated with long‐term and low‐dose glucocorticoid vol.24, pp.8, 2018, https://doi.org/10.1111/1756-185x.14164